Pertuzumab

From Anvita Health Wiki

Contents 1 Indications 2 Dosage 3 Adverse-effects 4 Mechanism-of-action 5 More General Terms 6 References

Indications

• Her2-positive metastatic breast cancer, in combination with trastuzumab & docetaxel

Dosage

• loading dose of 840 mg, followed by 420 mg every 3 weeks until disease progression or the development of unmanageable toxicity

Adverse-effects

• minimal additional adverse effects with the addition of pertuzumab to trastuzumab & docetaxel

Mechanism-of-action

• pertuzumab is a humanized monoclonal antibody that binds HER2 (at a different site than trastuzumab) & stimulates antibody-dependent, cell-mediated cytotoxicity
• synergy with trastuzumab

More General Terms

• monoclonal antibody
• antineoplastic agent (chemotherapeutic agent)

References

1. CLEOPATRA (CLinical Evaluation Of PertuzumAb and TRAstuzumab) trial: 34th Annual San Antonio Breast Cancer Symposium (SABCS): Abstract S5-5. Presented December 9, 2011

pertuzumab